News

Support the Coast-to-Coast Solo Run to Cure Alzheimer’s

Photo of Glenn Caffery

On May 19, 2011, Glenn Caffery, age 49, set out from Seaside, Ore., to run 3,312 miles across the country to Westerly, R.I. He is running to honor his father—Dick Caffery—whom he lost to Alzheimer’s disease in 2002, and to raise money to help find a cure for this devastating illness. “Watching my father suffer made me feel so helpless,” says Caffery. “Since he’s passed away, I’ve felt like I needed to do something to help, and running across the country felt like something.”

Coast-to-Coast Solo Run to Cure Alzheimer’s

Distance Runner to Raise Awareness, Research Funding for Alzheimer’s on 3,300-Mile Journey from Oregon to Rhode Island

Seaside, Oregon – Setting out on a 3,300-mile run from Seaside, Ore., to Westerly, R.I. to raise money and public awareness of Alzheimer’s disease, veteran distance runner and advocate Glenn Caffery compares the rigors of long distance running to the challenges facing 5.2 million Americans and their families who are dealing with the debilitating disease.

Alzheimer’s Association- a new beneficiary of The 7 Summits Climb for Alzheimer’s campaign

The 7 Summits Climb for Alzheimer’s: Memories are Everything is a year-long challenge by mountain climber and Alzheimer’s disease advocate Alan Arnette to scale the 7 summits, the highest peak on each continent. Alan is striving to raise $1 million to advance Alzheimer’s research, and provide support for family caregivers and all those affected by Alzheimer’s disease.

Rockefeller University Nobel Laureate awarded Cure Alzheimer's Fund research grant

Nobel laureate Paul Greengard, a Rockefeller University professor has been awarded a $100,000 grant by Cure Alzheimer’s Fund to continue his groundbreaking research on Alzheimer’s disease, the most common cause of dementia in the elderly that currently affects 5.2 million Americans and their families.

Paul Greengard, Ph.D., will use the grant to continue his studies on identifying brains cells that are vulnerable to Alzheimer’s. His studies could lead to the development of protective drugs targeted at those specific cells.

Cure Alzheimer’s Fund Awards Grant to University of Virginia for Innovative Research

Boston - A University of Virginia professor has been awarded a $100,000 grant by Cure Alzheimer’s Fund to continue his groundbreaking research on Alzheimer’s disease, the most common cause of dementia in the elderly, which currently affects 5.2 million Americans and their families.

George S. Bloom, Ph.D., will use the grant to continue his studies on a strain of antibodies thought to be able to recognize the proteins associated with Alzheimer’s.

Larry King highlights Alzheimer’s epidemic on CNN special Sunday, May 1

CNN will be airing the Larry King special “Unthinkable: the Alzheimer’s Epidemic” on Sunday, May 1 at 8:00 PM in most time zones. King will explore Alzheimer’s disease, the people it affects, its impact on their families, the latest in treatment, and why it is critical to find a cure for this devastating disease.

Progress for Alzheimer's in Washington

In September, Cure Alzheimer’s Fund representatives were invited by the White House to be panelists at a briefing on Alzheimer’s disease. At the White House Briefing on the Challenge of Alzheimer’s Disease in the United States, Tim Armour and Rudy Tanzi made presentations regarding the current state of Alzheimer’s research to senior members of the White House, Department of Health and Human Services, National Institutes of Health and representatives of many Alzheimer’s advocacy groups.

Bound for Everest

Fresh off of summiting Aconcagua, the highest peak in South America, Alan Arnette is at it again. This spring, he will attempt to summit Everest—the highest peak on Earth at 29,035 feet. Everest is the third mountain in his 7 Summits Climb for Alzheimer’s: Memories are Everything campaign—his yearlong mission to scale the highest peak on each of the seven continents to raise money for the fight against Alzheimer’s.

Relationship Between the APOE Genotype and Alzheimer's Disease

A meeting of the minds

One of the most important, outstanding genetic questions about Alzheimer’s disease is the relationship between the APOE genotype and the risk associated with the disease. To better understand this topic and speed progress, Cure Alzheimer’s Fund (CAF) sponsored a meeting in February 2010 to explore this issue. The body of biological knowledge regarding how and why APOE likely is linked with AD was discussed in detail by members of the CAF Research Consortium and Cheryl Wellington, Ph.D., University of British Columbia; Michael Brown, M.D., University of Texas; Karl Weisgraber, Ph.D., Gladstone Institute; Alan Tall, Ph.D., Columbia University; and Joachim Herz, M.D., University of Texas, whose record of research includes valuable insights into this relationship. The meeting led to some important, newly funded research, including a project by David Holtzman, M.D., in his lab at Washington University in St. Louis.